Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

STC Biologics Inc
Profile last edited on: 3/18/2016      CAGE: 5CEB3      UEI: ZLKFKJYE5FY7

Business Identifier: Biologic drugs
Year Founded
2008
First Award
2010
Latest Award
2015
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

763 D Concord Avenue
Cambridge, MA 02138
   (617) 899-0724
   info@stcbiologics.com
   www.stcbiologics.com
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

STC Biologics. Inc is a biotech company focusing on MAb biosimilar development. STC Biologics has a proprietary glycoanalysis platform enabling optimization of cell line conditions required for production of biologics with desired end glycosylation pattern. The firm's strategy is to develop cell lines for production of monoclonal antibody products for oncology and then partner with a large bio-manufacturer for scale up. Company currently working on cell line development for the first product, STC101. Firm aims to develop a high yield cell line with a post translational modification matching the branded equivalent.

Extent of SBIR involvement

User Avatar
Phase I Awards
2
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$599,881
Phase II Dollars
$0
Total Awarded
$599,881

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2015 1 NIH $300,000
Project Title: A Multi-Targeting Ligand Trap to Overcome Resistance in Braf Mutant Colorectal Cancer
2010 1 NIH $299,881
Project Title: Tas::75 0849::Tas The Goal Of This Project Is To Develop Stc Trastuzumab; A Gen

Key People / Management

  Magdalena Leszczyniecka -- President and CEO

  Eszter Birck-Wilson -- Co-Founder and Chief Technology Officer

  Zahra Shahrokh -- Chief Development Officer

Company News

There are no news available.